Konkuk University

About: Konkuk University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Population & Apoptosis. The organization has 13405 authors who have published 27027 publications receiving 506313 citations.

MIX: a mosaic Asian anthropogenic emission inventory for the MICS-Asia and the HTAP projects

Abstract: M. Li, Q. Zhang, J. Kurokawa, J.-H. Woo, K. B. He, Z. Lu, T. Ohara, Y. Song, D. G. Streets, G. R. Carmichael, Y. F. Cheng, C. P. Hong, H. Huo, X. J. Jiang, S. C. Kang, F. Liu, H. Su, and B. Zheng Ministry of Education Key Laboratory for Earth System Modeling, Center for Earth System Science, Tsinghua University, Beijing, China State Key Joint Laboratory of Environment Simulation and Pollution Control, School of Environment, Tsinghua University, Beijing, China Asia Center for Air Pollution Research, 1182 Sowa, Nishi-ku, Niigata, Niigata, 950-2144, Japan Department of Advanced Technology Fusion, Konkuk University, Seoul, Korea Energy Systems Division, Argonne National Laboratory, Argonne, IL, USA National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba, Ibaraki, 305-8506, Japan State Key Joint Laboratory of Environmental Simulation and Pollution Control, Department of Environmental Science, Peking University, Beijing, China

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Abstract: Cancer cells can evade immune surveillance through the molecular interactions of immune checkpoint proteins, including programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), cemiplimab (Libtayo®), atezolizumab (Tecentriq®), durvalumab (Imfinzi®), and avelumab (Bavencio®), which block the immune checkpoint proteins, have brought about a significant breakthrough in the treatment of a wide range of cancers, as they can induce durable therapeutic responses. In recent years, crystal structures of the antibodies against PD-1, PD-L1, and CTLA-4 have been reported. In this review, we describe the latest structural studies of these monoclonal antibodies and their interactions with the immune checkpoint proteins. A comprehensive analysis of the interactions of these immune checkpoint blockers can provide a better understanding of their therapeutic mechanisms of action. The accumulation of these structural studies would provide a basis that is essential for the rational design of next-generation therapies in immuno-oncology.

Search for Dark Matter and Large Extra Dimensions in pp Collisions Yielding a Photon and Missing Transverse Energy

Abstract: Results are presented from a search for new physics in the final state containing a photon and missing transverse energy. The data correspond to an integrated luminosity of 5.0 inverse femtobarns collected in pp collisions at sqrt(s)=7 TeV by the CMS experiment. The observed event yield agrees with standard-model expectations for photon plus missing transverse energy events. Using models for production of dark-matter particles (chi), we set 90% confidence level (CL) upper limits of 13.6--15.4 femtobarns on chi production in the photon plus missing transverse energy state. These provide the most sensitive upper limits for spin-dependent chi-nucleon scattering for chi masses between 1 and 100 GeV. For spin-independent contributions, the present limits are extended to chi masses below 3.5 GeV. For models with 3--6 large extra dimensions, our data exclude extra-dimensional Planck scales between 1.65 and 1.71 TeV at 95% CL.